Blue Trust Inc’s BioLineRX BLRX Stock Holding History

Blue Trust Inc’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3	Closed	–	–	2229
2023 Q4	$0	Buy	+3	New	+$186	﹤0.01%	2492
2023 Q3	–	Sell	-3	Closed	–	–	2044
2023 Q2	$0	Hold	3	–	–	﹤0.01%	2041
2023 Q1	$0	Buy	+3	New	+$79	﹤0.01%	2316

Other funds holding BLRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Blue Trust Inc's BLRX Position: Q1 2024 in Review

Blue Trust Inc sold out of BioLineRX (BLRX) in Q1 2024, closing a stake of 3 shares.

Blue Trust Inc first reported a position in BLRX in Q1 2023 and held it in 3 quarters. The position peaked at $0 in Q4 2023. 29 funds tracked by Wall St. Rank hold BLRX as of Q1 2024.

Blue Trust Inc reported no remaining BioLineRX position as of Q1 2024 after selling out during the quarter.
Blue Trust Inc sold 3 BioLineRX shares in Q1 2024.
Blue Trust Inc first reported a position in BioLineRX in Q1 2023 and held it in 3 quarters.
Blue Trust Inc's BioLineRX position peaked at $0 in Q4 2023.
29 funds tracked by Wall St. Rank held BioLineRX as of Q1 2024.

Based on Blue Trust Inc's 13F filing for Q1 2024, filed 1 May 2024.